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tObjective: To review and evaluate the literature of cost-utility analy-
ses (CUAs) regarding diagnostic laboratory testing. Methods: We re-
viewed all articles related to diagnostic laboratory testing in the Tufts
Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.
org), which contains detailed information on over 2000 published CUAs
through 2008. We analyzed the extent to which the studies adhered to
recommended practices for conducting and reporting cost-effective-
ness analyses. We also recorded whether the studies contained infor-
mation ondiagnostic test accuracy and costs, andwhether any account
was taken of potential benefits or harms of testing that are unrelated to
subsequent treatment, such as the reassurance value of testing.
Results: We identified 141 published CUAs pertaining to diagnostic
laboratory testing published through 2008 which contained 433 sepa-
rate incremental cost-effectiveness ratios. Prior to 2000, there were
only 20 CUAs published, but the number averaged 13.4 annually there-
after. Most studies focused on hematology/oncology (n  42, 30%) and
obstetrics/gynecology (n  36, 26%) applications. Approximately 63%
r the
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doi:10.1016/j.jval.2011.05.044n  89) of studies clearly reported information about the accuracy of
he test, but only 10% (n 14) mentioned test safety or possible risks. A
small number (n 10, 7%)mentioned or considered the potential value
or harm of testing unrelated to treatment consequences. Over 55% of
the reported incremental cost-effectiveness ratios (ICERs) were either
dominant (more quality-adjusted life years for less cost), or below
$50,000 per quality-adjusted life years gained (in 2008 US dollars).
Conclusion: The number of CUAs investigating laboratory diagnostic
testing has increased substantially with applications to diverse clinical
areas. The literature reveals many areas in which testing represents
good value formoney. The vastmajority of studies have not considered
preferences for test information unrelated to treatment consequences.
Keywords: cost-effectiveness, cost-utility, diagnostics, laboratory tests,
QALY.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The introduction of diagnostic laboratory techniques in clinical
practice has accelerated in recent decades [1]. The new techniques
have various aims: increasing certainty about the presence or ab-
sence of disease; supporting the clinical management of patients;
assessing prognosis; and/or monitoring the clinical course of dis-
ease. The emergence of these tests provides new options for clini-
cians and patients, though it has also raised concerns about inap-
propriate utilization [2,3]. Payers worldwide are asking whether
the benefits of new diagnostic laboratory testing are worth the
costs and, if so, in what circumstances [4]. The push to demon-
strate value has also meant more demanding questions about
whether testing directly improves patient outcomes and whether
benefits of testing outweigh the risks.
Cost-effectiveness analysis (CEA) provides a standard, well-ac-
cepted methodological technique for determining whether a
health intervention provides value for money, and is used to in-
form reimbursement and coverage decisions in many countries
[5–11]. Cost-utility analysis (CUA), a type of CEA in which the ben-
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.efits of an intervention are measured in terms of quality-adjusted
life years (QALYs) gained, incorporates the impact of an interven-
tion on patient’s mortality and morbidity. Because CUA allows
comparisons of value across diverse interventions and conditions
[12,13], they are used by many health authorities worldwide to
determine value for money and are recommended by many ex-
perts in health economics and outcomes research.
In conventional CUAs, test information is typically valued only
to the extent that it leads individuals and clinicians tomake better
medical decisions [14,15]. In practice, however, patients and
health-care providers may value information from a diagnostic
test even when the information does not change treatment deci-
sions [16]. A recent study, for example, found that cancer screen-
ing was favored by 87% of adults, even in the absence of effective
treatment options [17]. Of course, test information may also in-
duce harms unrelated to treatment consequences, such as in-
creased anxiety over test results.
CUA has been applied to a wide variety of health interventions
including pharmaceuticals [18], surgical procedures [19,20], and
diagnostic imaging [21,22] and is recommended by many experts
in health economics and outcomes research. One previous study
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1011V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8reviewed various types of published cost-effectiveness analyses
involving all kinds of diagnostic strategies [23]. In contrast, our
study systematically reviewed the CUA literature, focusing on di-
agnostic laboratory testing in different diseases. We evaluated
trends in themethods used to estimate cost-effectiveness, as well
as the extent to which they included key features pertinent to
diagnostic laboratory technologies, such as the cost and accuracy
of testing. We also explored the extent to which the QALY esti-
mates reflected preferences for test information unrelated to
treatment consequences.
Methods
We analyzed data from the Tufts Medical Center CEA Registry
(www.cearegistry.org) [24], a comprehensive database of over 2000
CUAs and over 5300 cost- utility ratios published in the peer-re-
viewed literature up to 2008. Data from the CEARegistry have been
used to review CUAs pertaining to various diseases and interven-
tions [18,21,25,26]. The protocol for searching and including stud-
ies in the Registry is described in detail elsewhere [24]. The Regis-
try comprises a systematic review, as each article undergoes a
formal systematic screening and review process. The procedure
starts with a MEDLINE search by keywords “QALYs”, “quality-ad-
justed” and “cost-utility analysis”. The search is limited to English-
language publications that contain original cost-utility estimates.
Reviews, editorials, and purely methodological articles are ex-
cluded, as are CEAs thatmeasure health effects in units other than
QALYs.
Each selected article is independently audited by two trained
reviewers for approximately 40 elements, including key study re-
sults, information characterizing study clarity and completeness,
and the methodological quality of the cost and utility weights in-
formation. The data collection form was designed based on sev-
eral published guidelines and recommendations for reporting
CUAs [12,27–31]. All reviewers have related background in health
economics and economic evaluations in health care and received
both training and detailed instructions to ensure the quality of
their input data. Reviewers also assign a subjective quality score
for each article (from 1 [low] to 7 [high]), which is based on factors
such as whether articles present: a correct computation of the
incremental cost-effectiveness ratios (ICERs); a comprehensive
characterization of uncertainty; an explicit specification of as-
sumptions; and an appropriate and explicit estimation of utility
weights. All ICERs are converted to 2008 US dollars using the for-
eign exchange rates for currency conversion and the consumer
price index (CPI) to adjust for inflation.
In this review, we selected all published CUAs that evaluated
one ormore diagnostic laboratory test. Tests were included if they
involved samples of blood, urine, or other tissues or substances in
the body [32]. In addition to the regularly audited variables [18], we
collected the following additional information for each analysis: 1)
clinical area of application (e.g., hematology/oncology, obstetrics/
gynecology, cardiovascular); 2) type of test (e.g., genetic, virology,
bacteriology, and immunology); and 3) the stage in which the test
is being adopted in the marketplace (i.e., innovative testing/feasi-
bility studies, commercially available/early adoption, or standard
of care/test included in treatment guidelines by relevant physician
organizations). Additional variables collected included whether
the study reported the cost of testing; the test accuracy (specifici-
ty/sensitivity); the consequences of inconclusive, indeterminate,
or inadequate results (e.g., whether one should conduct a different
test after the result of a test is inconclusive), and the potential risks
associatedwith testing (e.g., morbidity/mortality, adverse effects).
Finally, we evaluated whether the study estimated or mentioned
any consideration of the potential value or harm of testing unre-
lated to treatment, such as the value of reassurance, anxiety gen-
eration from false positive results, or other nonhealth attributes.We summarized the characteristics of all CUAs related to diag-
nostic laboratory tests, published through 2008.We also examined
the methods used and the quality of the study. We used Student’s
t-tests to determine differences in quality scores of studies in eval-
uating laboratory diagnostic testing versus other types of inter-
ventions. The trend test was adopted for analyzing changes of
study quality over time. Finally, we analyzed the distribution of
ICERs from selected CUAs. All statistic analyses were performed
using SAS 9.1 software (SAS, Cary, NC) with a definition of statis-
tical significance at P  0.05 for all tests.
Results
We identified 141 CUAs pertaining to diagnostic laboratory testing
published through 2008 (Fig. 1). The first study was published in
1985; since then the number of publications has increased rapidly
(Fig. 2). In the 15 years from 1985 and 1999, there were only 20
CUAs evaluating diagnostic laboratory testing; this number aver-
aged 13.4 annually after 2000. Publication characteristics are sum-
marized in Table 1. The analyses have been published in 86 differ-
ent journals, with the most frequently publishing journals being
Annals of Internal Medicine (n  8 CUAs), The American Journal of
Medicine (n  7), and The Journal of the American Medical Association
(n  7).
Most of the studies (n  88, 62.4%) were performed in the
United States, followed by studies conducted in the United
Kingdom (n  13, 9.2%) and Canada (n  6, 4.3%). The most
commonly cited funding source was government agencies (n 
70, 49.6%). CUAs most frequently applied to secondary preven-
tion defined as interventions aimed at alleviating disease by
early detection, and appropriate management (n  73, 51.8%);
27% (n  38) were for primary prevention (interventions aimed
at avoiding the onset of a symptom or disease) and 21.3% (n 
30) for tertiary prevention (interventions aimed at reducing the
complications and progression of existing disease). Fifty-three
studies (37.6%) investigated commercially available tests in
early stages of adoption, whereas over 50% (n  78) were for
Fig. 1 – Selection of studies and review process. CEA, cost-
effectiveness analysis; CUA, cost utility analyses; QALY,
quality-adjusted life year.tests considered current standard of care (Table 1). The diagnos-
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1012 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8tic tests were applied in diverse clinical areas, including: hema-
tology/oncology (n  42, 29.8%), obstetrics/gynecology (n  36,
5.5%), gastroenterology (n  34, 24.1%), endocrinology (n  20,
4.2%), and cardiovascular disease (n 10, 7.1%). In terms of the
ypes of testing, the CUAs focused most frequently on virology
ests (n 36, 25.5%), general chemistry tests (n 30, 21.3%), and
enetic testing (n  25, 17.7%).
The vast majority of studies adhered to recommended meth-
dological guidelines for conducting and reporting results, such as
learly presenting the intervention (99.3%); reporting the compar-
tor and target population (99.3%); stating the study perspective
98.5%), time horizon (84.4%), currency and year of currency
85.1%); applying discounting for future costs and QALYs, (92.9%);
onducting correct incremental analysis (94.3%); and performing
ensitivity analyses to probe uncertainties (98.6%) (Table 2). Most
tudies correctly calculated ICERs; only eight CUAs (5.7%) either
ncorrectly reported incremental ratios or did not report relevant
atios at all.
The mean quality score of the 141 diagnostic laboratory CUAs
as 4.41 (SD 1.01) comparedwith the quality of studies reported in
ther reviews using the CEA Registry data [24] was 4.27 (SD 1.06;
 0.1123). No statistical significant difference was found for the
tudy quality over time, such as whether study clearly stated tar-
et population, intervention and comparator; reported discounted
ate in both costs andQALYs; and correctly calculated incremental
ost-effectiveness ratios.
Approximately 63% of the CUAs reported the specificity and
ensitivity of the test in question. Only 37 studies (26.2%) men-
ioned a subsequent strategy for dealing with inconclusive, inde-
erminate or inadequate results – for example, to conduct addi-
ional testing (n  20), continue a work up if an inadequate result
as obtained (n  13), or repeat the same test (n  8). Only 14
tudies (9.9%) considered the safety or associated risks of the test
ither as a decrease in quality of life or as additional costs associ-
ted with complications related to testing.
A small proportion (n  10, 7.1%) of CUAs considered and dis-
ussed the potential value or harm of testing unrelated to treat-
ent consequences (Table 2). These studies considered various
spects related to these dimensions, including reassurance value
n 6), unnecessary worry about false-positive results (n 2), the
enefit of reducing uncertainty (n  1), or other attributes (n  6).
n 7 of 10 cases, these considerations of value were made in the
rticle’s discussion section, as opposed to being incorporated di-
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Fig. 2 – The growth in cost utility analyses (CUAs) ofectly into the QALY estimate (n  3).Table 3 highlights studies that have considered the potential
alue or harms of testing unrelated to treatment consequences.
hese studies tended simply to mention such factors in their dis-
ussion sections, but have not attempted to quantify them. Even
tudies that stated that they adjusted QALY estimates for non-
reatment considerations were generally vague about how esti-
ates were constructed. For example, a CEA of expanded testing
or primary HIV infection stated that “the utility of anxiety while
aiting for confirmatory test results for patients with a positive
creen is 0.682” [33] but did notmention how the utilityweightwas
alculated. Another study of the cost-effectiveness of sputum cy-
ology for lungmalignancy noted that they adjusted for the effects
f anxiety in the model, but did not include any details on the
easurement [34].
From the 141 CUAs, we identified 433 distinct ICERs (each arti-
lemay have one ormore ICERs). Themedian ratio value per QALY
ainedwas $36,000 (2008US$). Of the 433 ratios, 13.9% (n 60)were
ominant (QALY gains and cost-saving); whereas 43.4% (n  188)
ad cost-utility estimates below the commonly used $50,000 per
ALY gained threshold (Fig. 3). The proportion of ICERs that were
ound to be dominated (higher costs but less QALY gains) was
3.6% (n  59). Table 4 provides specific examples selected from
tudies with a quality score of 5 or higher. For instance, the re-
orted ICER of biennial fecal occult blood test in the United King-
omwas $4,700/QALY (2008US$) [35]. Comparedwith current hep-
titis B surface antigen assays in routine donor testing in European
ecipients of blood transfusions, new enhanced-sensitivity hepa-
itis B surface antigen assays resulted in $680,000 for each addi-
ional QALY [36].
Discussion
We reviewed all published CUAs of diagnostic laboratory tests
over the past 25 years to examine the study methodology and the
extent to which such testing has been found to reflect a cost-
effective use of resources. Our review also attempts to highlight
specific areas where standardization could result in improved
quality of diagnostic testing CEAs, and to monitor trends in the
quality of the available published studies. We found an increasing
number of published CUAs devoted to diagnostic laboratory test-
ing in recent years, which likely reflects the rising importance of
such testing in modern medicine, as well as concerns about in-
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similar to that of other types of medical interventions [26]. More
than half of reported ratios have a favorable cost-effectiveness
profile using conventional benchmarks for CUAs, suggesting that
many applications of testing evaluated and reported in economic
evaluations may represent good value for money.
The CUAs mostly targeted hematology/oncology, OB/GYN, en-
docrine disorders, and cardiovascular diseases. Approximately
Table 1 – Characteristics of CUAs of diagnostic
laboratory technology (N = 141).
Number Percent
Major publishing journal
Annals of Internal Medicine 8 5.7%
American Journal of Medicine 7 5.0%
Journal of American Medical
Association
7 5.0%
Transfusion 5 3.5%
Alimentary Pharmacology &
Therapeutics
4 2.8%
American Journal of Obstetrics and
Gynecology
4 2.8%
Pediatrics 4 2.8%
Study country
United States 88 62.4%
United Kingdom 13 9.2%
Canada 6 4.3%
The Netherlands 5 3.5%
Other/multi-countries 29 20.6%
Funding source*
Government 70 49.6%
Foundation 13 9.2%
Pharmaceutical/medical device
companies
13 9.2%
Healthcare organization 5 3.5%
None 9 6.4%
Other/could not be determined 44 31.2%
Prevention stage
Primary 38 27.0%
Secondary 73 51.8%
Tertiary 30 21.3%
Stage of adoption
New test, feasibility study or test
not commercially available
10 7.1%
Early adoption, commercially
available but not standard of care
53 37.6%
Standard of care/test included in
treatment guidelines by relevant
physician organization
78 55.3%
Clinical area of application
Hematology/oncology 42 29.8%
Obstetrics/gynecology 36 25.5%
Gastroenterology 34 24.1%
Endocrinology 20 14.2%
Cardiovascular 10 7.1%
Other 77 54.6%
Type of testing
Virology 36 25.5%
General chemistry 30 21.3%
Genetic 25 17.7%
General immunology 21 14.9%
Immunohematology/
immunohistochemistry
18 12.8%
Other 39 27.7%
* Each article may be sponsored by multiple funding sources.half of the tests involved simple virology and chemistry tech-niques, which typically have relatively low unit costs. Neverthe-
less, more expensive genetic testing has also emerged as an im-
portant tool to inform treatment decisions, such as testing of
BRCA1/BRCA2 for breast and ovarian cancer and testing of HLA-
B*5701 to guide initial therapy for HIV. Genetic testing was evalu-
ated in approximately 18% of the CUAs we reviewed. Given ongo-
ing development of “personalized medicine” tied to genetic
markers, this category may well expand in the future [37].
We found that the CUAs devoted to diagnostic laboratory test-
ing performed reasonably well on many quality metrics. For ex-
Table 2 – Methods used in CUAs for diagnostic
laboratory tests (n = 141).
Number Percent
Clear presentation of
Intervention 140 99.3%
Comparator 140 99.3%
Target population 140 99.3%
Time horizon
Lifetime 76 53.9%
Other 43 30.5%
Not stated 22 15.6%
Perspective
Societal 47 33.3%
Health-care payer 92 65.2%
Not stated/could not be determined 2 1.4%
Discounting
Cost or QALY only 9 6.4%
Both cost and QALY 116 82.3%
Not needed 6 4.3%
Not stated/could not be determined 10 7.1%
Currency and year
Yes, reported 120 85.1%
Incremental analysis
Correct 133 94.3%
Incorrect 5 3.6%
Could not be determined 3 2.1%
Sensitivity analysis
Yes, reported 139 98.6%
Accuracy, safety, and cost of the test
Considered the accuracy
(specificity/sensitivity) of the test?
89 63.1%
Considered inconclusive/indeterminate/
inadequate results?
37 26.2%
Conduct additional test 20 54.1%
Continue work up 13 35.1%
Repeat the same test 8 21.6%
Considered the safety or risk of the test? 14 9.9%
Morbidity/mortality 5 35.7%
Complication or adverse effects 8 57.1%
Reported costs of the test? 121 85.8%
Value of test unrelated to treatment
follow-up
Considered the value of the test unrelated
to treatment consequences?*
10 7.1%
Reassurance value 6 4.3%
Unnecessary worry about false-positive 2 1.4%
Ambiguity 1 0.7%
Other nonhealth attributes 6 4.3%
The information was located in the
QALY estimation 3 2.1%
Discussion 7 5.0%
CUA, cost utility analysis; QALY, quality-adjusted life year.* Not mutually exclusive.
1014 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8Table 3 – How articles considered the value of testing unrelated to treatment consequences.
Article Diagnostic laboratory test Consideration Location in CUA Notes
Kievit et al. 199048 Carcinoembryogenic antigen
monitoring
Other nonhealth
attributes
QALY estimation “. . .include the distress caused
by false-positive test results
and the fears associated
with early detection of an
incurable recurrence as well
as the morbidity and mortal-
ity related to operations per-
formed on account of either
false- or true-positive re-
sults.”
Raab et al. 199734 Sputum cytology for lung
malignancy
Reassurance,
ambiguity
QALY estimation “Adjustments for quality of life
are modeled for (1) the
diagnosis of cancer, (2) test-
related anxieties, and (3)
test complications . . .”;
”. . .we account for the ef-
fects of anxiety before, dur-
ing and after the test and the
pain and inconvenience of
the test. Test result-related
adjustments refer to con-
cerns patients may have
with the uncertainties of the
test result (false-negative di-
agnosis or false-positive di-
agnosis) and changes in
health consequent to a test
complication.”
Coco et al. 200533 1) HIV-1 RNA assay; 2) p24
antigen EIA; 3) third-g
Reassurance, other
nonhealth
attributes
QALY estimation “Utility of anxiety while
waiting for confirmatory
test results for patients with
a positive screen is 0.682.”
Homberger et al. 200549 21-Gene RT-PCR assay Reassurance, other
nonhealth
attributes
Discussion ”We deliberately omitted a
number of factors that may
further influence the clinical
utility and economics of the
assay. . .How the assay
might affect patients’ atti-
tudes about their decisions
has not been assess prospec-
tively,. . .”
Walensky et al. 200550 EIA test Reassurance, other
nonhealth
attributes
Discussion “. . .although the model in-
cluded quality-of-life esti-
mates for health states, the
short-term anxiety and fear
over the several days that
the patient awaits test re-
sults is difficult to capture
adequately when looking at
total life years as the clinical
endpoints. . .”
Ball et al. 200751 Pregnancy associated plasma
protein A, free B-HCG,
inhibin A, estriol, maternal
alfafetoprotein.
Reassurance Discussion “. . .It allows earlier reassur-
ance if the results return nor-
mal. . .”
Kobayashi et al. 20071 PSA Unnecessary worry in
false-positive
results,
reassurance
Discussion “. . .It is likely that participation
in the screening program
leads to impairment of QOL
for some men (e.g. those with
false positive PSA test re-
sults). . .Satisfaction with
their decision to participate”
Killie et al. 200752 Anti-HPA 1a antibodies
determination
Other nonhealth
attributes
Discussion “One may argue that women
who are informed that they
are at risk of having a child
with severe neurological
complications may develop
anxiety. . .”(continued)
1015V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8ample, the average quality score for the CUAs was compared with
the score for other intervention types [24]. Almost all studies ex-
plicitly stated the comparator, target population, time frame, and
study perspective; and most studies conducted sensitivity analy-
ses to examine the robustness of results.
Still, we identified several areas that would benefit from in-
creased standardization. For example, researchers, reviewers, and
publishers should make sure that studies evaluating diagnostic
laboratory technologies clearly state the accuracy and costs of
tests, and how often sampling or processing is not adequate and
what remedial steps to follow.
About one-third of CUAs did not consider or report the accu-
racy of the test under investigation. Most of these studies seemed
Table 3 – Continued.
Article Diagnostic laboratory test
Nielsen M et al. 200753 Genetic testing for MUTYH
mutations
Oth
a
Smith et al. 200754 DNA amplification assay for
Neisseria gonorrhoeae and
Chlamydia trachomatis)
Unn
f
r
EIA, enzyme immunoassay;
B-HCG, beta human
chorionic gonadotropin;
HPA, human platelet
antigens; MUTYH, mutY
Homolog (Escherichia coli);
QALY, quality-adjusted
life year; QOL, quality of
life; PSA, prostate-specific
antigen;
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Fig. 3 – Distribution of incremental cost-effectiveness ratios
US dollars (2008US$). QALY, quality-adjusted life year.to have implicitly assumed perfect accuracy of the tests. This may
be one reason why those studies did not consider the value or
harm unrelated to the treatment consequences, such as possible
anxiety from a false-positive result. For studies that did report test
accuracy, fewer than half considered a follow-up procedure for
indeterminate results. As a result, the risks and costs attributable
to follow-up management may have been underestimated. Inva-
sive diagnostic technologies, such as amniocentesis, chorionic vil-
lus sampling, or genetic testing, may sometimes be associated
with risks that can vary by the operator, the patient, or the test
itself. However, CUAs have rarely considered such factors.
Our study also found that few CUAs have considered prefer-
ences unrelated to treatment effects. Because they ignore such
ideration Location in CUA Notes
nhealth
tes
Discussion “. . .[W]e did not include the
psychosocial aspects of ge-
netic counseling in our anal-
ysis. People may experience
changes in their functional
emotional or social status af-
ter learning their genetic pre-
disposition.”. . .”because of
difficulties in measuring
non-health benefits. There is
a need for further research
on the psychosocial impact of
genetic services within a
health economics context”
sary worry in
ositive
Discussion “We did not consider the
possible harms of more
frequent screening: adverse
effects of false positive
screening on patients and
partners, the inconvenience
of obtaining test
specimens. . .”
-100K 100-200K 200K+ Dominated
S$/QALY
iagnostic laboratory tests (N = 433). Costs are given in 2008Cons
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1016 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8factors, existing CEAs of diagnostic testingmay underestimate the
true value of testing. Clinicians may prefer tests in part because
they reduce diagnosis uncertainty, even if patients do not actually
fare better after been tested [38]. Patients may favor testing due to
various factors, including their preference for reduced uncertainty
about their disease state or prognosis [14,39–42]. One recent sur-
vey found thatmost of respondentswould be inclined to take tests
predictive of future cancer, Alzheimer’s disease, or arthritis, even
in the absence of immediate treatment consequences [43]. Study
respondents valued testing for a host of nonmedical reasons (e.g.,
theywould live their lives differently or get their finances in order)
[43].
Future research should focus more on how to value diagnostic
testing beyond their influences in therapy. One recent study found
that awaiting breast biopsy provided greater stress for woman in
terms of anxiety and perceived stress than awaiting much riskier
invasive treatment of cancer [44]. To avoid over- or underestimat-
ing the value of diagnostic laboratory tests, we recommend that
the value of test information unrelated to treatment conse-
quences should be considered in future cost-effectiveness evalu-
ation. How to value the information or value “knowing for the sake
of knowing” will be an area of special interest and challenges for
the future research [39,43]. At the very least, authors of CEAs of
diagnostic laboratory tests should qualitatively discuss the poten-
tial benefits and harms, such as the “value of knowing” or in-
creased anxiety associated with testing, that were not captured in
the analysis. Beyond that, investigators might include the impli-
Table 4 – Selected cost-effectiveness results for diagnostic
Intervention vs comparator in target population
QFT alone vs TST followed by QFT (TST/QFT) in immunocompetent i
have had contact with sputum-smear-positive pulmonary tubercu
Screening for alpha-adducin Gly460Trp variant, and initiate diuretic
variant vs no screening and no diuretic treatment to any of the coh
white men and women treated for hypertension, not receiving diu
Biennial fecal occult blood test vs no screening in individuals aged 60
cancer through to the development of adenomatous polyps and m
subsequent death in the general population of England.
Universal newborn screening by tandem mass spectrometry (MS/MS
clinical course through age 20) vs no universal screening in neonat
Aggressive targeted screening: human papillomavirus test using poly
vs no screening in HIV-infected women with CD4 of 200–500/mm3
antiretroviral therapy.
Radical prostatectomy for all patients vs selection-based manageme
ploidy as an experimental marker (prostatectomy for nondiploid re
diploid result) in male patients diagnosed with moderately differen
score 5–7) prostate cancer, age 60.
IHC test: 1-year adjuvant trastuzumab for IHC 3 patients; standard
patients vs standard care in 55-year-old female with early breast c
excised and after 4 cycles of chemotherapy.
Pap test and human papilloma virus test every 2 years until the age o
years until the age of 100 in hypothetical cohort of US women, age
Screening for hepatitis C within prison population, possible follow-u
community for those positive in prison screening vs usual care – n
only symptomatic testing within community in prison population
New enhanced-sensitivity HBsAg assays in routine donor testing vs c
routine donor testing in European recipients of blood transfusions
Routine voluntary HIV counseling, testing, and referral screening vs
general population: prevalence of undiagnosed HIV 0.1%, annual in
Optical immunoassay alone with antibiotic treatment for positive re
with antibiotic treatment for positive results in adult patients with
beta-hemolytic Streptococcus pharyngitis.
Costs are given in 2008 US dollars (2008US$).
Source: Tufts Medical Center, the Cost-Effectiveness Analysis Registr
HBsAg, hepatitis B surface antigen; IHC, immunohistochemical; MC
ERON-TB Gold; TST, tuberculin skin test.cations of test information in the health state descriptions used intheir utility assessments; however, how to accomplish this with-
out unduly influencing respondent preferences will be a chal-
lenge. Additionally, more research from contingent valuation
studies on the willingness to pay for test information even where
there are no direct treatment implications would be helpful [43].
Health technology assessment (HTA) agencies worldwide are
intensifying their scrutiny of diagnostic laboratory tests and are
increasingly using information fromCEAs. Our study suggests that
HTA organizations might better account for individuals’ “value of
knowing” from such tests. A key policy question will be whether
and to what extent patients should pay themselves for such non-
health outcomes.
Our study has several limitations. First, studies were included
in the registry only if they met several peer-reviewed, English-
language, original CUAs presenting a cost per QALY ratio available
inMedline. Notwithstanding the limitations of our search strategy
and inclusion criteria, the sample of studies included in our review
is fairly large and diverse and likely is a broad representative of
studies available in this field. Previous evidence suggests that
manual searches and searches of databases other than Medline
have a limited incremental yield [45]. A study of economic evalu-
ations of laboratory diagnostics beyond CUAs would be helpful in
the future but also presents challenges in terms of comparing
studies with disparate endpoints.
Second, our measure of study quality was based on a 7-point
subjective Likert scale agreed upon by two expert readers and,
therefore, might have been subject to reader bias or not sensitive
ratory technology.
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1017V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 0 – 1 0 1 8scale has been analyzed and reported on in several previous pub-
lications, which found that the quality score was correlated with
factors such as the methodology used to conduct and report re-
sults of sensitivity analyses, as well as the quality and experience
of journals reporting results from economic evaluations
[18,21,22,26,46]. We did not judge the appropriateness of the com-
parator used in the incremental cost-effectiveness ratios. Further-
more, our results could be influenced by a publication bias (in
which positive results are published more often) that is found in
the general CUAs literature [47].
Finally, by summarizing and analyzing all articles published over
a20-yearperiodasagroup, slight changesand trends inpublications,
methodology, and/or inclusion of key parameters could have been
missed. The relatively low number of publications per year and vari-
ability in the quality of the studies, however, makes it impossible to
find statistical significance regarding finer details.
In conclusion, CEA of laboratory diagnostic testing has increased
rapidly in recent years and the information canhelpdecisionmakers
in their coverage and reimbursement decisions. Many of the CUAs
have adhered to key recommended protocols for the field. Very few
studies, however, have considered the potential value or harm of
testing unrelated to treatment consequences.
Source of financial support: This study was funded by a founda-
tion grant from the Institute for Health Technology Studies (In-
Health).
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